This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Saskatchewan directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Global phosphoproteomic analysis identifies SRMS-regulated secondary signaling intermediates.
Proteome science · 2018
FRK inhibits breast cancer cell migration and invasion by suppressing epithelial-mesenchymal transition.
Oncotarget · 2017
Spindle Checkpoint Factors Bub1 and Bub2 Promote DNA Double-Strand Break Repair by Nonhomologous End Joining.
Molecular and cellular biology · 2015
Latest funding
- $1,105,426
Telomere-Directed Epigenetic Therapy: A Novel Approach for Treating Pancreatic Ductal Adenocarcinoma.
CIHR · 2025 · Nominated PI
- $100,000
Targeting the EGFR/EphA2 crosstalk in triple negative breast cancer
CIHR · 2023 · Principal investigator
- $59,609
Targeting mitochondrial fission machinery in tumor-initiating cells
CIHR · 2022 · Co-investigator
3 publications.
Global phosphoproteomic analysis identifies SRMS-regulated secondary signaling intermediates.
Goel RK, Meyer M, Paczkowska M, Reimand J, Vizeacoumar F, Vizeacoumar F, Lam TT, Lukong KE
FRK inhibits breast cancer cell migration and invasion by suppressing epithelial-mesenchymal transition.
Ogunbolude Y, Dai C, Bagu ET, Goel RK, Miah S, MacAusland-Berg J, Ng CY, Chibbar R, Napper S, Raptis L, Vizeacoumar F, Vizeacoumar F, Bonham K, Lukong KE
Spindle Checkpoint Factors Bub1 and Bub2 Promote DNA Double-Strand Break Repair by Nonhomologous End Joining.
Jessulat M, Malty RH, Nguyen-Tran DH, Deineko V, Aoki H, Vlasblom J, Omidi K, Jin K, Minic Z, Hooshyar M, Burnside D, Samanfar B, Phanse S, Freywald T, Prasad B, Zhang Z, Vizeacoumar F, Krogan NJ, Freywald A, Golshani A, Babu M
Telomere-Directed Epigenetic Therapy: A Novel Approach for Treating Pancreatic Ductal Adenocarcinoma.
Principal investigators: Vizeacoumar, Franco J; Freywald, Andrew
Keywords: Pancreatic Cancer; Synthetic Dosage Lethality; Telomerase
Targeting the EGFR/EphA2 crosstalk in triple negative breast cancer
Principal investigators: Freywald, Andrew; Bisson, Nicolas; Dadachova, Ekaterina; Vizeacoumar, Franco J
Keywords: Bispecific Antibody; Breast Cancer; Genome-Wide Crispr Screening; Radioconjugates
Targeting mitochondrial fission machinery in tumor-initiating cells
Principal investigators: Leary, Scot
Keywords: Breast Cancer; Oncogenes And Tumour Suppressors; Targets And Biomarkers; Translational Research
Developing combination therapies for telomerase-overexpressing clear cell carcinoma of the ovaries
Principal investigators: Maranda, Vincent
Keywords: Clear Cell Carcinoma; Mouse Models; Ovarian Cancer; Patient-Derived Xenografts; Small Molecule Inhibitors; Synthetic Lethality; Telomerase
Identification of therapeutically relevant targets in telomerase overexpressing prostate cancers
Principal investigators: Vizeacoumar, Franco J; Freywald, Andrew
Keywords: Genome-Wide Crispr And Shrna Screens; Prostate Cancer; Synthetic Dosage Lethality; Telomerase
COVID-19 Variant Supplement - SARS-CoV2 therapeutic discovery through genetic screens and repurposing drugs that target essential virus-host interactions.
Principal investigators: Wilson, Joyce A; Vizeacoumar, Franco J
Keywords: Crispr Genomic Screen; High Throughput Screen; Sars-Cov2; Sars-Cov2 Replicon; Virus Host Interactions
SARS-CoV2 therapeutic discovery through genetic screens and repurposing drugs that target essential virus-host interactions.
Principal investigators: Wilson, Joyce A; Vizeacoumar, Franco J
Keywords: Crispr Genomic Screen; High Throughput Screen; Sars-Cov2; Sars-Cov2 Replicon; Virus Host Interactions
A systematic genome wide effort to identify and validate targetable synthetic dosage lethal interactions of mitotic kinases in colorectal cancer cells
Principal investigators: Vizeacoumar, Franco J; Freywald, Andrew
Keywords: Chromosomal Instability; Crispr-Cas9-Based Target Validation; Genetic Interactions; Genomics; Pooled Shrna Screening; Synthetic Dosage Lethality
Targeting the EphA2 receptor in triple-negative breast cancer
Principal investigators: Freywald, Andrew; Price, Eric W; Vizeacoumar, Franco J
Keywords: Combination Therapy; Epha2; Molecular Imaging Agents; Synthetic Antibody; Synthetic Lethality; Triple-Negative Breast Cancer
Systematic profiling of circular RNAs essential for the survival of cancer cells
Principal investigators: Vizeacoumar, Franco J; Geyer, Clarence R
Keywords: Circularrnas; Non-Coding Rnas
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Mohan Babu and Ashkan Golshani: 23 shared papers
- Mohan Babu and Andrew Freywald: 3 shared papers
- Mohan Babu and Zhaolei Zhang: 2 shared papers
- Andrew Freywald and Zhaolei Zhang: 2 shared papers
- Mohan Babu and Franco Vizeacoumar: 1 shared paper
- Andrew Freywald and Franco Vizeacoumar: 1 shared paper
- Andrew Freywald and Ashkan Golshani: 1 shared paper
- Andrew Freywald and Scott Napper: 1 shared paper
- Franco Vizeacoumar and Zhaolei Zhang: 1 shared paper
- Franco Vizeacoumar and Leda Raptis: 1 shared paper
- Franco Vizeacoumar and Ashkan Golshani: 1 shared paper
- Franco Vizeacoumar and Scott Napper: 1 shared paper
- Leda Raptis and Scott Napper: 1 shared paper
- Oncology
- Department of Biology
- DBMS
- Chemistry and Biochemistry
- Biochemistry
- Terrence Donnelly Centre for Cellular and Biomolecular Research
Co-authors at University of Saskatchewan, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Zhaolei Zhang
Terrence Donnelly Centre for Cellular and Biomolecular Research
1 shared papers, latest 2015
Ashkan Golshani
Department of Biology
1 shared papers, latest 2015
Leda Raptis
DBMS
1 shared papers, latest 2017
Scott Napper
Biochemistry
1 shared papers, latest 2017
Mohan Babu
Chemistry and Biochemistry
1 shared papers, latest 2015
Andrew Freywald
Oncology
1 shared papers, latest 2015
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.